Inhibikase Therapeutics Inc. (IKT)
IKT trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$1.76
-4.61% on the day
Market cap
$245.6M
Micro cap
Revenue · 2024
$0
-100.0% on 2023
Net income · 2024
-$27.5M
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2024.
Profile
| Field | Value |
|---|---|
| Ticker | IKT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001750149 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2024
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$27.5M |
| Operating income | -$28.6M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | -100.0% |
| Cash | $97.5M |
| Total assets | $98.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-12-19 |
| Latest annual report | 10-K | 2026-03-26 |
| Latest quarterly / interim | 10-Q | 2026-08-11 |
| Latest current report | 8-K | 2026-09-08 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 365 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SABS | SAB Biotherapeutics Inc. | $2.68 | -5.30% | $243.8M |
| IPSC | Century Therapeutics Inc. | $1.38 | -4.17% | $249.9M |
| FATE | Fate Therapeutics Inc. | $2.00 | -6.10% | $239.6M |
| PALI | Palisade Bio Inc. | $1.47 | -7.86% | $255.3M |
| XFOR | X4 Pharmaceuticals Inc. | $2.60 | -7.80% | $257.8M |
| LCTX | Lineage Cell Therapeutics Inc. | $0.9083 | -4.80% | $229.7M |
| LXEO | Lexeo Therapeutics Inc. | $2.74 | -9.87% | $224.8M |
| PLX | Protalix BioTherapeutics Inc. (DE) | $2.75 | -1.08% | $221.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier